8-KOther EventsExhibits & Filings

AbbVie Inc. 8-K Report, Corporate Update (Aug 18, 2026)

Filed August 18, 2026For Securities:ABBV

Summary

AbbVie Inc. (ABBV) has announced the successful completion of a substantial underwritten public offering of notes totaling $9.75 billion on August 18, 2026. This comprehensive financing effort includes a mix of senior floating rate notes due 2028 and various fixed-rate senior notes with maturities ranging from 2028 to 2066 and coupon rates from 4.500% to 6.100%. The proceeds from this offering are earmarked primarily to fund a portion of the acquisition of Apogee Therapeutics, Inc., with any remaining funds to be used for general corporate purposes. This significant debt issuance underscores AbbVie's strategic move to finance a key acquisition, demonstrating a commitment to growth through M&A. Investors should note the substantial principal amount raised and the diverse maturity profile of the notes. The filing also details certain redemption provisions and covenants associated with these new debt instruments, as well as a special mandatory redemption clause contingent on the completion of the Apogee acquisition.

Key Highlights

  • 1AbbVie successfully completed a $9.75 billion notes offering on August 18, 2026.
  • 2The offering includes $500 million in senior floating rate notes due 2028 and $9.25 billion in fixed-rate senior notes across multiple maturities (2028-2066).
  • 3Proceeds are intended to finance a portion of the acquisition of Apogee Therapeutics, Inc. and associated expenses.
  • 4The notes are unsecured and unsubordinated obligations of AbbVie, ranking equally with existing and future unsecured, unsubordinated indebtedness.
  • 5The offering was registered under the Securities Act of 1933 and details are described in a prospectus supplement.
  • 6Customary redemption provisions, including "make-whole" clauses for fixed-rate notes and a special mandatory redemption for most series if the Apogee acquisition is terminated.
  • 7The Indenture contains standard covenants, including limitations on liens and mergers/consolidations.

Frequently Asked Questions

The primary purpose of this $9.75 billion notes offering is to fund a portion of the aggregate cash consideration for AbbVie's previously announced acquisition of Apogee Therapeutics, Inc., as well as to pay related fees and expenses. Any remaining proceeds will be used for general corporate purposes.

AbbVie issued a combination of senior floating rate notes and fixed-rate senior notes. Specifically, there was $500 million in senior floating rate notes due 2028. The fixed-rate notes include $1 billion due 2028, $1.25 billion due 2030, $1.5 billion due 2031, $1.25 billion due 2033, $1.5 billion due 2036, $1 billion due 2038, $1.5 billion due 2056, and $500 million due 2066, bringing the total fixed-rate notes to $9.25 billion. The total principal amount of the offering is $9.75 billion.

This offering significantly increases AbbVie's total debt. The unsecured and unsubordinated nature of these notes means they rank equally with other senior unsecured debt. While this financing supports a strategic acquisition that could drive future growth, investors should monitor the impact of increased leverage on the company's financial flexibility and credit metrics. The various maturities and interest rates will also affect future interest expenses and cash flow requirements.

If AbbVie publicly announces the termination of the definitive agreement for the Apogee acquisition or notifies the Trustee that it will not pursue the acquisition, AbbVie is required to redeem all of the Floating Rate Notes, 2028 Notes, 2030 Notes, 2031 Notes, 2033 Notes, 2036 Notes, and 2038 Notes then outstanding. These notes will be redeemed at a special mandatory redemption price of 101% of their principal amount, plus accrued and unpaid interest. The 2056 and 2066 Notes are excluded from this special mandatory redemption.